Logo image of OXUR.BR

OXURION NV (OXUR.BR) Stock Fundamental Analysis

EBR:OXUR - Euronext Brussels - BE0974487192 - Common Stock - Currency: EUR

0.185  -0.01 (-5.13%)

Fundamental Rating

0

Taking everything into account, OXUR scores 0 out of 10 in our fundamental rating. OXUR was compared to 73 industry peers in the Biotechnology industry. OXUR has a bad profitability rating. Also its financial health evaluation is rather negative. OXUR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OXUR had negative earnings in the past year.
OXUR had a negative operating cash flow in the past year.
OXUR had negative earnings in each of the past 5 years.
In the past 5 years OXUR always reported negative operating cash flow.
OXUR.BR Yearly Net Income VS EBIT VS OCF VS FCFOXUR.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

OXUR has a worse Return On Assets (-249.85%) than 84.72% of its industry peers.
Industry RankSector Rank
ROA -249.85%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OXUR.BR Yearly ROA, ROE, ROICOXUR.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

OXUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OXUR.BR Yearly Profit, Operating, Gross MarginsOXUR.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

0

2. Health

2.1 Basic Checks

OXUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
OXUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OXUR.BR Yearly Shares OutstandingOXUR.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
OXUR.BR Yearly Total Debt VS Total AssetsOXUR.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

OXUR has an Altman-Z score of -37.44. This is a bad value and indicates that OXUR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of OXUR (-37.44) is worse than 84.72% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -37.44
ROIC/WACCN/A
WACC7.74%
OXUR.BR Yearly LT Debt VS Equity VS FCFOXUR.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

OXUR has a Current Ratio of 0.08. This is a bad value and indicates that OXUR is not financially healthy enough and could expect problems in meeting its short term obligations.
OXUR has a Current ratio of 0.08. This is amonst the worse of the industry: OXUR underperforms 88.89% of its industry peers.
OXUR has a Quick Ratio of 0.08. This is a bad value and indicates that OXUR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.08, OXUR is doing worse than 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
OXUR.BR Yearly Current Assets VS Current LiabilitesOXUR.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.54%, which is quite impressive.
Looking at the last year, OXUR shows a very negative growth in Revenue. The Revenue has decreased by -83.69% in the last year.
The Revenue for OXUR have been decreasing by -45.20% on average. This is quite bad
EPS 1Y (TTM)98.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.77%
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-49.79%
Revenue growth 5Y-45.2%
Sales Q2Q%-99.44%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OXUR.BR Yearly Revenue VS EstimatesOXUR.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
OXUR.BR Yearly EPS VS EstimatesOXUR.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OXUR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OXUR.BR Price Earnings VS Forward Price EarningsOXUR.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OXUR.BR Per share dataOXUR.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OXUR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OXURION NV

EBR:OXUR (3/7/2025, 7:00:00 PM)

0.185

-0.01 (-5.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2024-09-30
Earnings (Next)N/A N/A
Inst Owners0.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap673.40K
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-32.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0.02
BVpS-4.07
TBVpS-4.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -249.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -37.44
F-Score2
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)2.17%
Cap/Depr(5y)3.36%
Cap/Sales(3y)4.38%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-49.79%
Revenue growth 5Y-45.2%
Sales Q2Q%-99.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.85%
OCF growth 3YN/A
OCF growth 5YN/A